LUNG CANCER

Daniel S. Oh, MD, assistant professor of surgery, University of Southern California, Keck School of Medicine, discusses myPlan genetic testing in patients with lung cancer.

By adding bevacizumab (Avastin) to a standard chemotherapy doublet, the risk of death is reduced by 24%, with the risk of disease reducing by 39%, in patients who have malignant pleural mesothelioma (MPM).

The majority of patients under the age of 40 who have lung cancer had tumors with mutations that can be targeted with existing therapies.

The FDA recently granted alectinib a priority review designation for patients who have ALK-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) and progressed or are intolerant to crizotinib (Xalkori).

Lung cancer is the leading cause of cancer-related mortality worldwide, with approximately 1.6 million deaths annually.

The standard of care for lung cancers has been dramatically transformed by the growing availability of molecular diagnostics and genetic testing, and by targeted therapies that specifically inhibit a number of well-established oncogenic drivers.

Nivolumab (Opdivo) was given a priority review designation by the FDA for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC).

Malignant mesothelioma is an uncommon malignancy of the pleura that is usually associated with asbestos exposure.

An application for afatinib (Gilotrif) was recently accepted by the FDA for the treatment of patients with squamous cell non-small cell lung cancer (NSCLC).

Roy S. Herbst, MD, PhD, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven, discusses immunotherapy in squamous and nonsquamous non-small cell lung cancer (NSCLC).

On November 7, 2015, some of the leading experts in oncology, together with other oncology healthcare professionals involved in the treatment and management of patients with lung cancer, will gather in Manhattan for the 10th Annual New York Lung Cancer Symposium®.

The majority of lung cancers are non–small cell lung cancers (NSCLCs), which are associated with several gene mutations.

A fluorescent molecular contrast agent accurately identified 92% of lung adenocarcinomas during pulmonary surgery.

While targeting HER2 mutations is mainly associated with breast cancer, there could be therapeutic potential with anti-HER2 agents in non-small cell lung cancer (NSCLC).

Precision medicine with TKIs and immunotherapies is revolutionizing the treatment of patients with NSCLC. Paul A. Bunn, Jr, MD, head of the Division of Medical Oncology at the University of Colorado, discussed the current translational advances with these agents in a discussion held at this year’s International Lung Cancer Congress.

Clinical trial designs are experiencing a huge transformation geared toward the discovery and confirmation of new predictive biomarkers for patients who have non-small cell lung cancer (NSCLC), as well as other types of solid tumors.

Paul A. Bunn, Jr., MD, distinguished professor, Division of Medical Oncology, University of Colorado, James Dudley Chair in Lung Cancer Research, Lung Cancer: Giant of Cancer Care, discusses immunotherapy in lung cancer.

Walter J. Curran, Jr., MD, FACR, associate vice president of cancer, Woodruff Health Sciences Center, executive director, Winship Cancer Institute, Lawrence W. Davis Chair of Radiation Oncology, Emory University, discusses radiation therapy dose for the treatment of patients with lung cancer.

A new drug application (NDA) was recently submitted for rociletinib (CO-1686) as a treatment for patients who have EGFR T790M-positive metastatic non-small cell lung cancer (NSCLC) following previous administration of an EGFR TKI.

After a successful demonstration as single-agents, clinical trials are currently assessing PD-1 and PD-L1 inhibitors, combined with chemotherapy, targeted therapies, and radiation therapy, in an attempt to further improve outcomes for patients who have non-small cell lung cancer (NSCLC).

Barbara J. Gitlitz, MD, associate professor of clinical medicine, Keck Medicine, University of Southern California, discusses EGFR mutations in patients with lung cancer.

Next generation therapies proven to be highly effective, are in development for patients who have oncogene-driven non-small cell lung cancer (NSCLC), specifically those with alterations in EGFR, ALK, ROS1, and NTRK.

Roy Decker, MD, PhD, associate professor of therapeutic radiology, assistant professor of surgery (Otolaryngology), Clinical Research Program Leader, Therapeutic Radiology, Yale University, discusses stereotactic body radiation therapy (SBRT) in surgery for patients with early non-small cell lung cancer (NSCLC).

In addition to late patient presentation, the high mortality rate in lung cancer can be largely attributed to the complex nature of the disease and a very high rate of heterogeneity in the causative molecular abnormalities.

Immunotherapies (immune checkpoint inhibitors) and targeted therapies (tyrosine kinase inhibitors [TKIs] that target specific mutations in one or more oncogenic drivers) represent two of the most researched types of therapy under investigation for the treatment of non-small cell lung cancer (NSCLC).

An impressive array of newly approved treatments, as well as investigational agents, for non–small cell lung cancer (NSCLC) emerged in the first 6 months of 2015.

Martin Reck, MD, PhD, Head of Thoracic Oncology, Hospital Grosshansdorf, discusses the phase III SQUIRE trial in patients with non-small cell lung cancer (NSCLC) treated with necitumumab.

The University of Texas MD Anderson Cancer Center in Houston has been selected as the site for one of two new Genome Characterization Centers (GCCs) funded by the National Cancer Institute (NCI) and National Institute of Health (HHSN261200800001E).

Breakthrough therapy designation has been granted by the US Food and Drug Adminstration (FDA) to the combination of the BRAF inhibitor dabrafenib (Tafinlar) and the MEK inhibitor trametinib (Mekinist) as treatment for patients with BRAF V600E-mutant non–small cell lung cancer

Nivolumab (Opdivo) was recently approved by the European Commission as a treatment for patients who have locally advanced or metastatic squamous non-small cell lung cancer (NSCLC), following prior chemotherapy, based on findings from the phase III Checkmate-017, as well as the phase II Checkmate-063 trials.